Efficacy and tolerability of amlodipine in the general practice treatment of essential hypertension in an Asian multinational population

Clinical Drug Investigation

Volumn 16, Issue 3, 1998, Pages 177-185

  Taylor, Stanley H ^a,i   Chen, Ming Fong ^b   Lee, Simon Jong Koo ^c   Koanantakul, Banhan ^d   Zhu, J R ^e   Santoso, Teguh ^f   Sy, Rody G ^g   Tai, Yau Ting ^h  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Asan Medical Center   (South Korea)

^d BHUMIBOL ADULYADEJ HOSPITAL   (Thailand)

^e ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^f CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^g PHILIPPINE GENERAL HOSPITAL   (Philippines)

^h UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; AMBULATORY MONITORING; ANUS PRURITUS; ARTICLE; ASIAN; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; GENERAL PRACTICE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0031668838     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816030-00001     Document Type: Article

References (34)

1. Zanchetti A, Chalmers J, Arakawa K, et al. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-18
2. Kannel WB. Potency of vascular risk factors as the basis for antihypertensive therapy. Eur Heart J 1992; 13 Suppl. G: 34-42
3. Collins R, Peto R, McMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2: short-term reductions in blood pressure - overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-39
4. Kaplan NM. Amlodipine in the treatment of hypertension. Postgrad Med J 1991; 67 Suppl. 5: S15-9
5. Mroczek WJ, Burris JF, Allenby KS. Effects of amlodipine on 24-hour ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S13-5
6. Morris AD, Meredith PA, Reid JL. Pharmacokinetics of calcium antagonists: implications for therapy. In: Epstein M, editor. Calcium antagonists in clinical medicine. Philadelphia: Haley & Belfus, 1992: 49-67
7. Meredith PA, Elliott HL. Amlodipine: clinical relevance of a unique pharmacokinetic profile. J Cardiovasc Pharmacol 1993; 22 Suppl. A: S6-8
8. Abernethy DR, Schwartz JB. Pharmacokinetics of calcium antagonists under development. Clin Pharmacokinet 1988; 15: 1-14
9. Silke B, Goldhammer E, Taylor SH. An exercise haemodynamic comparison of verapamil, diltiazem and amlolipine in coronary heart disease. Cardiovasc Drugs Ther 1990; 4: 457-64
10. Packer M, Lee WH, Medina N, et al. Comparative negative inotropic effects of nifedipine and diltiazem in patients with severe left ventricular dysfunction. Circulation 1985; 72 Suppl. III: III-275
11. Kubota K, Pearce GL, Inman WHW. Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring. Eur J Clin Pharmacol 1995; 48: 1-7
12. Faulkner JK, McGibney D, Chasseaud LF, et al. The pharmacokinetics of amlolipine in healthy volunteers after single intravenous and oral doses and after repeated oral doses given once daily. Br J Clin Pharmacol 1986; 2: 21-5
13. Burges RA, Dodd MG, Gardiner DG. Pharmacological profile of amlodipine. Am J Cardiol 1989; 64: 101-201
14. Leenen FHH, Fourney A, Notman G, et al. Persistence of antihypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41: 83-8
15. Detry JMR, Block P, DeBacker G and the Belgian Collaborative Study Group. Patient compliance and therapeutic coverage: comparison of amlodipine and slow-release nifedipine in the treatment of hypertension. Eur J Clin Pharmacol 1995; 47: 477-81
16. Varrone J and the investigators of study AML-NY-86-002. The efficacy and safety of amlodipine in the treatment of mild and moderate essential hypertension in general practice. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S30-3
17. Abernethy DR, Gutowska J, Lambert MD. Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol 1988; 12 Suppl. 17: S67-71
18. Osterloh IH. The safely profile of amlodipine. Am Heart J 1989; 188 (5. Pt 2): 1114-20
19. Glasser SP, Chrysant SG, Graves J, et al. Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension. Am J Hypertens 1989; 2: 154-7
20. Burris JF, Ames RP, Applegate WB, et al. Double blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1988; 12 Suppl. 7: S98-102
21. Davies J, Jensen H, Garsdal P. A double-blind comparison of amlodipine and placebo added to open enalapril in patients with moderate to severe essential hypertension. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S16-8
22. Maclean D, Mitchell ET, Wilcox RG, et al. Amlodipine and captopril in moderate-severe essential hypertension. J Hum Hypertens 1988; 1: 127-32
23. Hwang JJ, Chen JJ. Once-daily amlodipine on ambulatory blood pressure and regression of left ventricular hypertrophy in patients with mild to moderate essential hypertension. JAMA SE Asia 1995; 11 Suppl. 4: 10-5
24. Ding YA, Chang SM, Chen TC. Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension. JAMA SE Asia 1995; 11 Suppl. 4: 16-21
25. Lin SJ, Chen CH, Chiang CE. Effects of amlodipine and enalapril on ambulatory blood pressure and serum lipids in elderly patients with isolated systolic hypertension. JAMA SE Asia 1995; 11 Suppl. 4: 22-9
26. Chen YT, Huang JL, Lin CJ. Effects of amlodipine on arterial compliance and wave reflection in essential hypertension. JAMA SE Asia 1995; 11 Suppl. 4: 30-4
27. Agabiti-Rosei E, Muiesan ML, Rizzone R, et al. Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J Cardiovasc Pharmacol 1994; 24 Suppl. A: S37-43
28. Hoegholm A, Wiinberg N, Rasmussen E, et al. Comparative effects of amlodipine and felodipine ER on office and ambulatory blood pressure in patients with mild to moderate hypertension. J Hum Hypertens 1995; 9 Suppl. 1: S25-8
29. Meredith PA, Perloff D, Mancia G, et al. Blood pressure variability and its implications for antihypertensive therapy. Blood Press 1995; 4: 5-11
30. Mancia G, Giannattasio C, Ombori S. Ambulatory blood pressure monitoring and antihypertensive treatment. Eur Heart J 1992; 13 Suppl. G: 43-7
31. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983; 75 Suppl. 3A: 4-11
32. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure. Insights from the Framingham Study. J Cardiovasc Pharmacol 1987; 10 Suppl. 6: S135-40
33. Taylor SH. Toward comprehensive cardiovascular protection with amlodipine. JAMA SE Asia 1995; 11 Suppl. 4: 35-53
34. Julius S. Amlodipine in hypertension: an overview of the clinical dossier. J Cardiovasc Pharmacol 1988; 12 Suppl. 7: S27-33